Skip to main navigation Skip to search Skip to main content

Protocol No. CAMN107AUS37: "Phase II Randomized, Multicenter Study of Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Patients Who Achieve and Sustain MR4.5 after Switching to Nilotinib"

Project: Research project

Project Details

StatusFinished
Effective start/end date9/1/14 → 12/31/20

Funding

  • Novartis Pharmaceuticals Corporation ( Award # ): $94,543.00